IRB #

IRB00010178

Title

The Safety and Effectiveness of the VaricElla zosteR VaccinE (VERVE) in Anti-TNF Users

Principal Investigator

Kevin Winthrop

Study Purpose

To evaluate the safety of the Zoster Vaccine in patients using Anti-TNF Therapies

Medical Condition(s)

Protection against shingles in individuals with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis

Eligibility Criteria

50 years or older
Have rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis
Currently recieving an Anti-TNF therapy

Age Range

50 - 95

Healthy Volunteers Needed

No

Duration of Participation

Up to 7 weeks, with annual follow-up if the real vaccination is received

Minors Included

No

Contact

Sarah Siegel 503 494 1384

Sponsor

American College of Rheumatology

Recruitment End

10/31/2016

Compensation Provided

Yes

Compensation

You will receive $25 for completing the screening visit and $75 for six-week follow up visit. If you withdraw before the end of the study, you will be paid for the visits you have completed. If you complete the entire study, you will receive $100.


Go Back